EagleClaw Capital Management’s Merck MRK Stock Holding History

EagleClaw Capital Management’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.81M	Sell	31,638 -325	-1%	-$37.5K	0.53%	52
2025 Q4	$3.36M	Buy	31,963 +120	+0.4%	+$11.3K	0.49%	54
2025 Q3	$2.67M	Buy	31,843 +25	+0.1%	+$2.06K	0.37%	69
2025 Q2	$2.52M	Hold	31,818	–	–	0.38%	70
2025 Q1	$2.86M	Buy	31,818 +1,000	+3%	+$93.4K	0.45%	63
2024 Q4	$3.07M	Buy	30,818 +1,450	+5%	+$149K	0.49%	61
2024 Q3	$3.34M	Sell	29,368 -1,400	-5%	-$166K	0.56%	54
2024 Q2	$3.81M	Sell	30,768 -50	-0.2%	-$6.44K	0.69%	43
2024 Q1	$4.07M	Sell	30,818 -200	-0.6%	-$24.7K	0.74%	46
2023 Q4	$3.38M	Sell	31,018 -45	-0.1%	-$4.67K	0.7%	49
2023 Q3	$3.2M	Buy	31,063 +750	+2%	+$80.8K	0.73%	49
2023 Q2	$3.5M	Sell	30,313 -855	-3%	-$97.1K	0.8%	47
2023 Q1	$3.32M	Sell	31,168 -50	-0.2%	-$5.4K	0.78%	46
2022 Q4	$3.46M	Hold	31,218	–	–	0.84%	45
2022 Q3	$2.69M	Buy	31,218 +730	+2%	+$65.2K	0.75%	47
2022 Q2	$2.78M	Sell	30,488 -1,473	-5%	-$131K	0.75%	43
2022 Q1	$2.62M	Buy	31,961 +179	+0.6%	+$14.1K	0.6%	53
2021 Q4	$2.44M	Sell	31,782 -1,275	-4%	-$102K	0.53%	54
2021 Q3	$2.49M	Buy	33,057 +20	+0.1%	+$1.52K	0.64%	53
2021 Q2	$2.57M	Buy	33,037 +327	+1%	+$24.3K	0.66%	47
2021 Q1	$2.4M	Buy	32,710 +2,468	+8%	+$182K	0.69%	47
2020 Q4	$2.36M	Sell	30,242 -3,768	-11%	-$288K	0.75%	43
2020 Q3	$2.69M	Sell	34,010 -628	-2%	-$49.2K	0.94%	33
2020 Q2	$2.55M	Sell	34,638 -7,938	-19%	-$598K	0.99%	29
2020 Q1	$3.12M	Hold	42,576	–	–	1.47%	22
2019 Q4	$3.69M	Buy	42,576 +7,570	+22%	+$622K	1.35%	21
2019 Q3	$2.81M	Buy	35,006 +5,374	+18%	+$431K	1.15%	26
2019 Q2	$2.38M	Hold	29,632	–	–	1.03%	28
2019 Q1	$2.35M	Sell	29,632 -367	-1%	-$27.4K	1.07%	27
2018 Q4	$2.19M	Buy	29,999 +52	+0.2%	+$3.67K	1.15%	26
2018 Q3	$2.02M	Buy	29,947 +1,677	+6%	+$107K	0.89%	35
2018 Q2	$1.64M	Sell	28,270 -78	-0.3%	-$4.4K	0.79%	42
2018 Q1	$1.47M	Hold	28,348	–	–	0.75%	50
2017 Q4	$1.52M	Buy	28,348 +943	+3%	+$52.3K	0.77%	52
2017 Q3	$1.67M	Sell	27,405 -26	-0.1%	-$1.58K	0.95%	42
2017 Q2	$1.68M	Hold	27,431	–	–	0.98%	38
2017 Q1	$1.67M	Sell	27,431 -545	-2%	-$33.1K	1%	36
2016 Q4	$1.57M	Sell	27,976 -105	-0.4%	-$6.14K	0.99%	38
2016 Q3	$1.67M	Hold	28,081	–	–	1.07%	36
2016 Q2	$1.54M	Hold	28,081	–	–	1.03%	35
2016 Q1	$1.42M	Hold	28,081	–	–	0.96%	39
2015 Q4	$1.41M	Hold	28,081	–	–	0.94%	40
2015 Q3	$1.32M	Hold	28,081	–	–	0.93%	41
2015 Q2	$1.52M	Sell	28,081 -26	-0.1%	-$1.46K	0.98%	41
2015 Q1	$1.54M	Sell	28,107 -105	-0.4%	-$5.95K	0.99%	40
2014 Q4	$1.53M	Sell	28,212 -53	-0.2%	-$2.95K	1.01%	39
2014 Q3	$1.6M	Buy	28,265 +158	+0.6%	+$8.87K	1.09%	39
2014 Q2	$1.55M	Sell	28,107 -210	-0.7%	-$11.5K	1.05%	41
2014 Q1	$1.53M	Buy	+28,317	New	+$1.47M	1.11%	38

Other funds holding MRK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EagleClaw Capital Management's MRK Position: Q1 2026 in Review

EagleClaw Capital Management reduced its Merck (MRK) stake by 1% in Q1 2026, selling an estimated $37.5K and leaving 31,638 shares worth $3.81M. The position accounts for 0.53% of the portfolio, ranked #52.

EagleClaw Capital Management first reported a position in MRK in Q1 2014 and has held it in 49 quarters since. The position peaked at $4.07M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

EagleClaw Capital Management held 31,638 shares of Merck worth $3.81M as of Q1 2026.
EagleClaw Capital Management sold 325 Merck shares in Q1 2026, an estimated $37.5K.
Merck made up 0.53% of EagleClaw Capital Management's portfolio in Q1 2026, its #52 holding.
EagleClaw Capital Management first reported a position in Merck in Q1 2014 and has held it in 49 quarters since.
EagleClaw Capital Management's Merck position peaked at $4.07M in Q1 2024.
3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on EagleClaw Capital Management's 13F filing for Q1 2026, filed 8 May 2026.